Morbidity and GH deficiency: a nationwide study.

Area of Science:

• Endocrinology
• Public Health
• Epidemiology

Background:

• Growth hormone deficiency (GHD) is a complex endocrine disorder.
• Understanding the full spectrum of morbidity associated with GHD is crucial for patient care.
• Previous studies have indicated potential health risks for GHD patients.

Purpose of the Study:

• To quantify and characterize the overall morbidity in a large cohort of patients diagnosed with GHD in Denmark.
• To compare morbidity rates between GHD patients and a matched control group.
• To investigate differences in morbidity based on the age of GHD onset (childhood vs. adult).

Main Methods:

• A retrospective cohort study analyzing data from 1794 GHD patients and 8014 matched controls.
• Utilized the Danish National Patient Registry to identify diagnoses and admission dates.
• Calculated hazard ratios (HRs) for overall and cause-specific morbidity, stratified by sex and GHD onset group (childhood onset [CO] and adult onset [AO]).

Main Results:

• GHD patients exhibited significantly increased total morbidity compared to controls (HRs ranging from 2.9 to 3.2 across subgroups).
• Elevated morbidity was observed across numerous disease categories, including infectious, endocrine, pulmonary, neurological, and neoplastic diseases.
• Specific increases were noted in fractures for adult-onset GHD females.

Conclusions:

• Morbidity is substantially elevated in individuals with GHD, affecting a wide range of health conditions.
• While some increased morbidity is attributable to GHD and associated pituitary deficiencies, other causes remain unexplained.
• These findings underscore the need for comprehensive health monitoring in GHD patients.